NextCure and Avere Therapeutics Announce Merger and $320 Million Financing to Create Oral IL-23 Biotech

Rallybio Corporation to Acquire Avenzo Therapeutics in $215M Financing Deal

June 2, 2026

Biotechnology

Rallybio Corporation entered into a definitive merger agreement to acquire Avenzo Therapeutics, with the combined company expected to operate as Avenzo Therapeutics, Inc. and trade on Nasdaq under the ticker symbol AVZO. The transaction includes a concurrent, oversubscribed $215 million private placement with participation from healthcare institutional investors and mutual funds, and is expected to close in Q4 2026 subject to customary conditions.

Asahi Kasei to Acquire Aicuris Anti-infective Cures AG

February 26, 2026

Pharmaceuticals

Asahi Kasei entered into a definitive agreement to acquire Aicuris Anti-infective Cures AG, a German biopharmaceutical company, for approximately €780 million. The acquisition is designed to expand Asahi Kasei’s specialty pharmaceutical platform into severe infectious diseases and to complement its existing transplant and nephrology franchises. A second article reports Asahi Kasei completed the acquisition.

Aerovate Therapeutics to Merge with Jade Biosciences

April 7, 2025

Biotechnology

Aerovate Therapeutics announced it expects to declare a cash dividend to its pre-merger stockholders in connection with its previously announced merger with Jade Biosciences. The cash dividend is expected to total $67.6 million to $69.6 million, with the closing expected no later than April 30, 2025 and subject to stockholder approvals and customary closing conditions.

AbbVie Acquires Nimble Therapeutics in $200 Million Deal

January 23, 2025

Biotechnology

AbbVie announced and later completed the acquisition of Nimble Therapeutics for $200 million in cash at closing, plus interim funding and potential development milestone payments to Nimble shareholders. The deal adds Nimble’s preclinical oral peptide IL23R inhibitor for psoriasis/IBD and its proprietary peptide synthesis, screening, and optimization platform to strengthen AbbVie’s immunology pipeline and R&D capabilities.

Adaptimmune Therapeutics And TCR² Therapeutics To Merge (All-Stock)

March 6, 2023

Healthcare Services

Adaptimmune Therapeutics plc and TCR² Therapeutics Inc announced they have entered into a definitive agreement to merge in an all-stock transaction, combining to form a preeminent cell therapy company focused on solid tumors. The merged company will leverage complementary engineered T-cell technology platforms (SPEAR and TRuC) and is expected to extend its cash runway into 2026 following closing.

Eli Lilly and Company to Acquire Prevail Therapeutics

December 15, 2020

Biotechnology

Eli Lilly and Company announced a definitive agreement to acquire Prevail Therapeutics for $22.50 per share in cash, plus a non-tradable contingent value right (CVR) worth up to $4.00 per share, for total consideration of up to approximately $1.04 billion. The acquisition is intended to establish a gene therapy program within Lilly anchored by Prevail’s AAV9-based neuroscience pipeline. Lilly expects the transaction to close in the first quarter of 2021, subject to customary closing conditions and regulatory approvals.